Marwan N Sabbagh
St. Josep's Hospital and Medical Center, Phoenix · St. Joseph's Hospital and Medical Center, Phoenix · Barrow Neurological Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marwan N Sabbagh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06639282 · Repurposing Siponimod for Alzheimer's DiseaseSt. Joseph's Hospital and Medical Center, Phoenix · recruiting · Alzheimer Disease, Mild Alzheimer Disease, MCI With Increased Risk for Alzheimer Disease · principal investigator
- Ph2NCT04032626 · MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsSt. Joseph's Hospital and Medical Center, Phoenix · completed · Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque · principal investigator
- N/ANCT02759887 · Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)St. Joseph's Hospital and Medical Center, Phoenix · completed · Down Syndrome, Alzheimer's Dementia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Repurposing Siponimod for Alzheimer's DiseaseR01AG073212 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · fiscal years 2021 to 2026 · $684,437 awarded in 2026Grant number is on one of their registry trials
- MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsR01AG059008 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · fiscal years 2018 to 2023 · $701,731 awarded in 2023Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pre-clinical testing of lenalidomide as pleiotropic therapeutics of Alzheimer's diseaseK01AG047279 · NIA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Boris Decourt · fiscal years 2015 to 2019Named on NCT04032626
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:57 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.Alzheimers Dement · 2015468 citationsRCR 17.4
- Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.Arch Neurol · 2005332 citationsRCR 8.3
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.JAMA Neurol · 2015267 citationsRCR 9.5
- Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.Alzheimers Dement · 2013208 citationsRCR 7.0
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.Alzheimers Res Ther · 2024185 citationsRCR 28.6
- 162 citationsRCR 5.6
- PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.Alzheimer Dis Assoc Disord · 2011137 citationsRCR 4.1
- Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.Neurobiol Aging · 2013115 citationsRCR 3.9
- Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.Acta Neurol Scand Suppl · 200699 citationsRCR 2.7
- Reduced risk of incident AD with elective statin use in a clinical trial cohort.Curr Alzheimer Res · 200899 citationsRCR 2.5